Sanofi, Evotec and Apeiron Biologics enter collaboration to develop novel small molecule immuno-oncology treatments
- Details
- Category: Sanofi
Sanofi has entered a research collaboration and license agreement with Evotec and Apeiron Biologics to discover and develop first-in-class small molecule-based immuno-oncology therapies to treat solid and hematological cancers by enhancing the anti-tumor activity of the human immune system.
Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Circuit Therapeutics have announced a second collaboration using Circuit's proprietary optogenetics technology platform. This new three-year collaboration will focus on investigating metabolic disorders with the aim of developing novel medicines to improve the treatment of obesity and associated diseases.
"Roche Continents" fosters innovation in science and art
- Details
- Category: Roche
Today, Roche welcomed 100 European university students from 34 countries studying science and art to the Salzburg Festival, the world's largest and most prestigious festival of music and drama. The annual Roche Continents week offers highly talented undergraduate and graduate students the opportunity to explore sources of inspiration at the intersection of science and music through structured workshops and challenges.
AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments
- Details
- Category: AstraZeneca
AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.
MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer
- Details
- Category: AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer.
Pfizer and Synthon enter into U.S. commercialization agreement for potential generic treatment of multiple sclerosis
- Details
- Category: Pfizer
Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone® for the treatment of relapsing remitting multiple sclerosis (RRMS).
Bristol-Myers Squibb establishes collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has announced the establishment of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of Immuno-Oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.
More Pharma News ...
- AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
- Merck announces application period for start-ups
- Bayer significantly improves earnings
- AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa
- European Commission approves Amgen's new cholesterol-lowering medication Repatha™ (evolocumab)
- AstraZeneca completes agreement with Tillotts Pharma for Entocort
- Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients